ESGO-EOTTD-ISSTD-GCIG Gestational trophoblastic disease guidelines

In 2023, the European Society of Gynaecological Oncology (ESGO), the European Organization for Treatment of Trophoblastic Disease (EOTTD), the International Society for the Study of Trophoblastic Disease (ISSTD) and the Gynecologic Cancer InterGroup (GCIG) have launched a new project aiming at developing guidelines on the management of patients with gestational trophoblastic disease that would comprehensively cover the complete management of this rare disease.

The development group involved more than 50 clinicians worldwide with expertise in treatment of the GTD and specialized in gynaecologic oncology, medical oncology and pathology.

The guidelines were developed under the leadership of Prof. Michael Seckl from the United Kingdom (ESGO), Dr. Christianne Lok from the Netherlands (EOTTD), Prof. Ros Berkowitz from the United States of America (ISSTD) and Prof. Ioana Braicu from Germany (GCIG).

 

ESGO-EOTTD-ISSTD-GCIG Gestational trophoblastic disease guidelines Working Group

ESGO, EOTTD, ISSTD and GCIG would like to express their sincere gratitude to the international experts panel, who devoted their time and effort to the EOTTD-ESGO-ISSTD-GCIG Guidelines for the management of patients with Gestational Trophoblastic Disease.

List of working group members

External reviewers

24 reviewers  - 15 countries

ESGO would also like to thank external reviewers who have taken the time to provide their feedback on the document elaborated in the framework of the EOTTD-ESGO-ISSTD-GCIG Guidelines for the management of patients with Gestational Trophoblastic Disease.

List of external reviewers